Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

55.6%

5 terminated/withdrawn out of 9 trials

Success Rate

37.5%

-49.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

4(44.4%)

9Total

Phase 2(5)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02689921Phase 2Unknown

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Role: lead

NCT01325584Phase 2Terminated

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Role: lead

NCT02486796Phase 1Terminated

Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer

Role: lead

NCT03061110Phase 1Withdrawn

Stromal Vascular Fraction for Treatment of Xerostomia

Role: lead

NCT02952742Phase 2Withdrawn

Black Cohosh for Host Flashes Due to Androgen Deprivation Therapy

Role: lead

NCT02521077Phase 2Withdrawn

Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

Role: lead

NCT02496533Phase 2Completed

Patient Anxiety During Radiological Examination

Role: lead

NCT01163110Phase 1Completed

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

Role: lead

NCT00441207Phase 1Completed

Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors

Role: lead

All 9 trials loaded